SCHEMBL20606887

SCHEMBL20606887

Cc1cc(C#N)nnc1-c1cn(C)nc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ S1PR2 O95136 13/20 0.50
▸ CYP2C19 P33261 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CDK2 P24941 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ BRD4 O60885 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21940484 0.84 CYP2C19 (0.43) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9
SCHEMBL21940579 0.84 S1PR2 (0.40) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9
SCHEMBL20606814 0.84 S1PR2 (0.42) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9
SCHEMBL20606966 0.82 COMT (0.36) S1PR2SMN1; SMN2ALDH1A1
SCHEMBL20606795 0.82 S1PR2 (0.39) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9
SCHEMBL21940282 0.81 S1PR2 (0.41) S1PR2CYP2C19CYP1A2CYP2C9HTT
SCHEMBL21819827 0.81 S1PR2 (0.41) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9
SCHEMBL21940475 0.81 S1PR2 (0.42) S1PR2CYP2C19CYP1A2CYP2C9HTT
SCHEMBL21940276 0.79 S1PR2 (0.40) S1PR2ALDH1A1
SCHEMBL21940479 0.77 CYP2C19 (0.41) S1PR2CYP2C19CYP3A4CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423445-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2020-04-01 — — EP disclosed
EP-3423445-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2020-04-01 — — EP disclosed
EP-3423445-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS Galapagos NV (BE) 2019-01-09 — — EP disclosed
Send feedback